After further review, Merck ends nemtabrutinib cancer drug development program
Landon Capital News
Merck (MRK) has discontinued its entire BELLWAVE clinical development program evaluating nemtabrutinib (MK-1026), an investigational oral BTK inhibitor being studied for patients with chronic lymphocytic leukemia, small lymphocytic leukemia, and other blood cancers.
The decision followed a review by an external Data Monitoring Committee of the Phase 3 BELLWAVE-011 trial, which suggested the benefits may not outweigh the risks. Merck confirmed the finding after conducting its own review of the full data set, and subsequently chose to discontinue the broader program, including Phase 3 studies BELLWAVE-008 and BELLWAVE-010.
“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program,” said Dr. Marjorie Green, senior vice president and head of global oncology clinical development at Merck Research Laboratories.
Merck said it is notifying study investigators and advising patients to consult their study teams and physicians about next steps and treatment options. Data analyses for the trials are ongoing, and Merck said results will be shared with the scientific community.
About Landon Capital News
Landon Capital News is a media company that is wholly owned by Landon Capital Management LLC. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.
Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of any kind. This press release is the news that we have researched to be true and accurate to our best ability. Landon Capital does not share the sentiment of the news that is released, we are just reporting a news event. Landon Capital received no direct compensation related to this release. This release may contain certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof through already public resources. Actual results may differ materially from those stated or implied in.